Medidata Cloud Technology Selected to Support Biogen Clinical Trials

NEW YORK--()--Medidata (NASDAQ: MDSO) today announced that its cloud technology has been selected by Biogen to support future clinical trials. Biogen will increase its adoption of Medidata Rave®—the world’s leading solution for capturing, managing and reporting patient data—and Medidata TSDV, a solution that maximizes the efficiency of costly data verification.

The agreement expands an existing relationship to use Rave and TSDV across Biogen’s diverse clinical development portfolio, which includes potential therapies for neurological, autoimmune and rare diseases.

“Medidata is thrilled to provide Biogen with next-generation technology to help accelerate scientific innovation,” said Medidata’s CEO Tarek Sherif. “We look forward to expanding this relationship and contributing to Biogen’s efforts to pursue novel treatments as they seek to improve the standard of care for patients living with serious unmet medical conditions.”

The expanded use of Medidata’s technology platform aims to enhance study planning and execution, site performance and data quality across Biogen’s clinical development programs.

In supporting more than 11,000 clinical studies for customers worldwide, 420,000 investigational sites and more than 3.1 million trial participants, the Medidata platform is powering a transformation in clinical trial design and execution, leading to better science and new medical treatments for patients. Medidata’s cloud technology is allowing researchers to translate millions of pieces of patient data—drawn from numerous devices and technologies—into clear, actionable insights about the efficacy, safety, tolerability and appropriate dosage of medical treatments.

Connect with Medidata

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. We are committed to advancing the competitive and scientific goals of our life sciences customers worldwide: more than 700 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. Our industry-leading technology platform, the Medidata Clinical Cloud®, is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, bringing new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting.

Contacts

Medidata
Investor:
Medidata Solutions
Hulus Alpay, +1 212-419-1025
halpay@mdsol.com
or
Media:
Medidata Solutions
Nicole Pariser, +1 212-659-1069
npariser@mdsol.com

Social Media Profiles

Contacts

Medidata
Investor:
Medidata Solutions
Hulus Alpay, +1 212-419-1025
halpay@mdsol.com
or
Media:
Medidata Solutions
Nicole Pariser, +1 212-659-1069
npariser@mdsol.com